Reports of Practical Oncology and Radiotherapy最新文献

{"title":"Recurrent glioblastoma: a typical example of a complex approach.","authors":"Naciri Meryem, Bouchbouk Soufiane, El Majjaoui Sanaa, Naim Asmae, Ismaili Nabil","doi":"10.5603/rpor.104738","DOIUrl":"https://doi.org/10.5603/rpor.104738","url":null,"abstract":"","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"30 1","pages":"126-128"},"PeriodicalIF":1.2,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11999010/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144015756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring vimentin expression and its protein interactors across diverse cancer types via the cancer genome atlas datasets: a comprehensive analysis.","authors":"Małgorzata Blatkiewicz, Piotr Białas, Olga Taryma-Leśniak, Szymon Mazgaj, Beata Hukowska-Szematowicz, Anna Jankowska","doi":"10.5603/rpor.104142","DOIUrl":"https://doi.org/10.5603/rpor.104142","url":null,"abstract":"<p><strong>Background: </strong>The global burden of cancer is escalating, with millions of individuals diagnosed and succumbing to the disease each year. Early detection is crucial for improving patient outcomes, yet many cancers are identified at advanced stages. Vimentin (VIM) has emerged as a promising biomarker with significant diagnostic and prognostic potential.</p><p><strong>Materials and methods: </strong>This study investigates <i>VIM</i> expression and promoter methylation across various cancers using The Cancer Genome Atlas (TCGA) datasets. Additionally, we analyze protein-protein interactions and mutation frequencies using advanced bioinformatics tools.</p><p><strong>Results: </strong>Our findings reveal that <i>VIM</i> is overexpressed in seven cancer types, including cholangiocarcinoma, glioblastoma multiforme, and breast invasive carcinoma. Notably, <i>VIM</i> expression is correlated with promoter methylation in specific cancers. Furthermore, we identify complex protein interactions involving <i>VIM</i>, highlighting its role in critical cellular processes such as proliferation and apoptosis.</p><p><strong>Conclusion: </strong>These insights emphasize Vimentin's multifaceted role in cancer, suggesting its potential as both a therapeutic target and a diagnostic marker.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"30 1","pages":"88-99"},"PeriodicalIF":1.2,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11999022/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Establishing a radiation oncology department in India: key challenges and essential considerations from the perspective of radiation oncology professionals.","authors":"Sweta Soni, Amit Kumar Sharma, Venugopal Sundaram, Chandan Dev Singh Katoch","doi":"10.5603/rpor.104386","DOIUrl":"https://doi.org/10.5603/rpor.104386","url":null,"abstract":"<p><p>Cancer continues to be a major factor in global mortality rates, presenting a substantial challenge to efforts aimed at extending life expectancies worldwide. Effective cancer treatment necessitates a multidisciplinary approach. India has a limited number of radiotherapy centres, and their distribution is uneven between urban and rural areas. Setting up a radiotherapy department is a complex process that demands thorough planning. The establishment of new radiotherapy departments involves a series of interconnected steps such as regulatory support, site selection, infrastructure design, civil works, recruitment of professional staff, equipment procurement, commissioning, and obtaining licenses. Mobilizing human resources, including training and forming a skilled team consisting of radiation oncologists, medical physicists, technologists, nursing officers, and support staff, is essential for proficient operation and patient care. Effective master planning for new radiotherapy facilities necessitates collaboration and involvement of highly specialized professionals from both the healthcare sector and the construction industry. Conducting a cost-benefit analysis is vital to ensure that the proposed facility meets the institute's objectives in terms of patient workload and clinical capability with sufficient institutional resources to support the program. The strategic placement of functional areas not only improves patient workflow and optimizes shielding needs but also enhances communication within the broader institution. In addition, designing a radiotherapy facility with vision and adaptable expansion capabilities ensures cost efficiency, allowing seamless evolution in response to future demands while maintaining uninterrupted services. Therefore, the article aims to discuss the challenges, and strategies for establishing a new radiation oncology department.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"30 1","pages":"114-121"},"PeriodicalIF":1.2,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11999006/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144050188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In smokers, the axis NCAPG/hsa-let-7b-5p/TMPO-AS1 promotes lung adenocarcinoma.","authors":"Prerna Vats, Sakshi Nirmal, Rajeev Nema","doi":"10.5603/rpor.104388","DOIUrl":"https://doi.org/10.5603/rpor.104388","url":null,"abstract":"<p><strong>Background: </strong>Smoking is linked to high morbidity and mortality rates of lung cancer, emphasizing the need for a better understanding of prognosis-related mRNA/miRNA/lncRNA-ceRNA networks.</p><p><strong>Materials and methods: </strong>The study utilized databases like OncoMX, The University of ALabama at Birmingham CANcer data (UALCAN), OncoDB, ENCORI, Kaplan-Meier (KM) Plotter, miRNet, CancerMIRNome, TISIDB, and TIMER2.0 to analyze <i>NCAPG</i>/miRNA and LncRNA expression in lung cancer tumors and healthy tissues.</p><p><strong>Results: </strong>The <i>NCAPG</i> gene is overexpressed in lung cancer cells. High <i>NCAPG</i> expression is associated with adenocarcinoma patients with a log fold change of 8.7 in case of tumor <i>vs</i>. normal samples (t = 515, n = 59). Overexpression of <i>NCAPG</i> indicates poor overall survivability in lung adenocarcinoma (LUAD) patients [hazard ratio (HR) = 1.6, confidence interval (CI) = 1.34-1.9, p = 9.9e-08] and those with a smoking history (HR = 1.44, CI = 1.11-1.87, p = 0.0062), but not significantly associated with lung squamous cell carcinoma (LUSC). miRNA hsa-let-7b-5p negatively correlates (R = -0.348) with <i>NCAPG</i> expression, with its down expression associated with poor survivability (HR = 0.71), while lncRNA TMPO-AS1 positively correlates (R = 0.575) with the <i>NCAPG</i> axis, with its overexpression associated with poor survivability (HR = 2.16).</p><p><strong>Conclusion: </strong>Elevated levels of <i>NCAPG</i> and TMPO-AS1 in lung adenocarcinoma patients lead to aggressive growth and poor prognosis. miRNA hsa-let-7b-5p, a key miRNA, may inhibit these factors, potentially improving patient prognosis. Further research and clinical trials are needed to validate this targeted therapy.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"30 1","pages":"44-53"},"PeriodicalIF":1.2,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11999020/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144022054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementation and validation of the method for the energy spectra reconstruction of electron beams generated by the AQURE mobile accelerator.","authors":"Adam Ryczkowski, Bartosz Pawałowski, Marta Małgorzata Kruszyna-Mochalska, Agnieszka Misiarz, Agata Jodda, Przemysław Adrich, Tomasz Piotrowski","doi":"10.5603/rpor.104511","DOIUrl":"https://doi.org/10.5603/rpor.104511","url":null,"abstract":"<p><strong>Background: </strong>The energy spectrum is the main component of the Monte Carlo model of the electron beam. One possible method to obtain it is a backward reconstruction from the measured depth dose distribution, owing to solving the inverse first-degree Fredholm integral equation with appropriate regularisation. This study aimed to reconstruct and validate energy spectra for mobile intraoperative accelerators.</p><p><strong>Materials and methods: </strong>The Geant4 package was used to simulate percentage depth dose (PDD) distributions. The micro-Diamond detector and the BeamScan water phantom were used to measure PDD. 160 PDDs were simulated for quasi-monoenergetic beams with energies from 0 to 20 MeV for a 10 cm diameter applicator. Using the simulated and measured PDDs, energy spectra were reconstructed for all available nominal energies by solving the inverse Fredholm equation. A single Gaussian peak was used as a reference solution, and the regularisation parameter λ was set to 0.05. Obtained spectra were used to simulate PDD for 5 and 6 cm applicators and compared with the measurements.</p><p><strong>Results: </strong>Simulated and measured PDDs were compared using the gamma analysis method with 2% DD and 2 mm distance to agreement (DTA) criteria. Measured and simulated PDDs agree perfectly for the 4 MeV beam. For higher energies, the PDDs agree at all depths except for depths less than 2 mm.</p><p><strong>Conclusion: </strong>The numerical solution of the inverse Fredholm equation with Tikhonov regularisation using simulated annealing optimisation is a reliable method to reconstruct the energy spectrum for electron beams produced by mobile intraoperative accelerators.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"30 1","pages":"62-70"},"PeriodicalIF":1.2,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11999011/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143988020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the efficacy of nivolumab and ipilimumab in renal cell carcinoma: insights from a district hospital cohort study.","authors":"Artur Drobniak, Mirosława Puskulluoglu, Łukasz Stokłosa, Renata Pacholczak-Madej","doi":"10.5603/rpor.104389","DOIUrl":"https://doi.org/10.5603/rpor.104389","url":null,"abstract":"<p><strong>Background: </strong>Nivolumab and ipilimumab combination is recommended as a first-line treatment for metastatic renal cell carcinoma (mRCC) in patients without life-threatening symptoms. This study aims to assess the efficacy and safety of this treatment regimen administered in the one-day chemotherapy unit of a district hospital.</p><p><strong>Materials and methods: </strong>We conducted a retrospective study involving 36 patients diagnosed with mRCC who had received combined immunotherapy at the Department of Chemotherapy, District Hospital in Sucha Beskidzka, Poland. We evaluated treatment response and adverse events (AEs). Laboratory parameters were recorded, and we calculated neutrophil-lymphocyte ratios (NLR), platelet-lymphocyte ratios (PLR), and lymphocyte-monocyte ratios (LMR) at baseline, after 3 months of treatment, and prior to disease progression.</p><p><strong>Results: </strong>After a median follow-up of 11 months (7.5-17.5 months), the median overall survival was not reached (NR, 6.7-NR), while the median progression-free survival was 11.5 months (6.7-NR). The objective response rate was 30.6% (n = 11), and the disease-control rate was 66.7% (n = 24). Hemoglobin and eosinophil levels varied at three checkpoints, without differences in NLR, PLR, and LMR. AEs of any grade were observed in 23 patients (63.9%) with a median onset time of 3 months (2-4 months), and serious AEs in 13.8% of patients (n = 5).</p><p><strong>Conclusions: </strong>Our analysis suggests that the combination of nivolumab and ipilimumab for mRCC has an acceptable toxicity profile and can be effectively managed in a district hospital's outpatient clinic. This approach requires close patient monitoring and collaboration with other hospital departments to ensure patient safety and treatment efficacy.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"30 1","pages":"34-43"},"PeriodicalIF":1.2,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11999007/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144042022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Results of radical treatment of locally advanced rectal cancer in geriatric and non-geriatric patients.","authors":"Abrahams Ocanto, Ramón Cantero, Rosa Morera, Raquel Ramírez, Isabel Rodríguez, Katherine Castillo, Pilar Samper, Felipe Couñago","doi":"10.5603/rpor.104387","DOIUrl":"https://doi.org/10.5603/rpor.104387","url":null,"abstract":"<p><strong>Background: </strong>It is estimated that 60% of new rectal cancer cases will be diagnosed in patients ≥ 65 years old. The geriatric patient is heterogeneous and underrepresented in clinical trials, and oncologic therapies are often tailored with little evidence. We describe a cohort of patients diagnosed with locally advanced rectal cancer in geriatric and non-geriatric patients.</p><p><strong>Materials and methods: </strong>Retrospective and descriptive analysis of 137 patients, 44 (32.1%) ≥ 75 years old and 93 (67.9%) ≤ 75 years old, with diagnosis of locally advanced rectal cancer. All patients received neoadjuvant chemoradiotherapy (nCRT), followed by total mesorectal excision (TME) and adjuvant chemotherapy.</p><p><strong>Results: </strong>Mean age was 79.5 for ≥ 75 years and 62.7 for ≤ 75 years, tumor location was: upper rectum (16.1% and 11.3%), middle rectum (60.2% and 47.7%) and lower rectum (23.7% and 41%), using the Eastern Cooperative Oncology Group (ECOG) 0: 74.1% and 81.8%, ECOG 1: 25.9% and 18.2%. Pathological complete response was 21.5% and 22.7%, partial response, 57% and 59% and no response, 21.5% and 18.3%, respectively. Tumor shrinkage in both groups after neoadjuvant treatment was 34.5% and 35.46%. Local recurrence was 2.2% and 3.2% and distance recurrence, 11.3% and 8.6%, respectively.</p><p><strong>Conclusion: </strong>The study shows similar outcomes in both groups following radical treatment, with similar rates of pathological complete response. However, it has notable limitations, including a small sample size and the absence of a comprehensive geriatric assessment. To enhance these findings, future research should involve larger patient cohorts with comparative analysis and clinical trials specifically focused on the geriatric population.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"30 1","pages":"54-61"},"PeriodicalIF":1.2,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11999012/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144042044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dosimetric advantage of ipsilateral lung and cardiac sparing of left breast cancer prone position compared with supine free breathing in the COVID-19 era and personalized medicine.","authors":"Vincent Vinh-Hung, Melpomeni Kountouri, Nicolas Benziane-Ouaritini, Odile Fargier-Bochaton, Giovanna Dipasquale, Mohamed Laouiti, Olena Gorobets, Raymond Miralbell, Paul Sargos, Nam P Nguyen","doi":"10.5603/rpor.104143","DOIUrl":"https://doi.org/10.5603/rpor.104143","url":null,"abstract":"<p><strong>Background: </strong>As coronavirus disease 19 (COVID-19) run unabated across the globe, its potential survival detrimental effects on lung function may be potentiated by systemic therapy and/or radiotherapy. Limiting lung exposure to high radiation dose in addition to sparing the heart may be critical for left-sided breast cancer patients. Deep inspiration breath-hold allows heart sparing. However, a minority of patients cannot hold breath for radiotherapy. We aim to evaluate whether a prone setup can be advantageous in these patients.</p><p><strong>Materials and methods: </strong>Left breast cancer patients who had dual supine and prone planning, both in free-breathing, were retrospectively identified. A multiple-structures penalty score was computed from the mean absolute dose deviation (MADD) to heart, lungs, breasts, and tumor bed for each supine and prone plan. Dosimetric advantage of prone was assessed by the reduction of penalty score compared with supine. Patients' characteristics effect on the reduction of penalty was analyzed using robust linear regression.</p><p><strong>Results: </strong>The prone <i>vs</i>. supine MADD for 27 patients demonstrated significant sparing for the ipsilateral lung and was 0.6 <i>vs</i>. 3 Gy, respectively, without differences regarding heart and target volumes. The average penalty ± standard deviation was 0.90 ± 0.28 Gy prone, <i>vs</i>. 1.13 ± 0.38 Gy supine, p = 0.024. Overall, 70.4% (19/27) patients had a reduction of penalty with prone setup, as compared with 29.6% (8/27) supine, p = 0.0065. Pre-dosimetry characteristics could not predict the reduction of penalty.</p><p><strong>Conclusion: </strong>Prone conferred substantial lung sparing without dose-deterioration to other structures, providing a significant advantage as compared with supine free-breathing radiotherapy in left-breast cancer patients.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"30 1","pages":"11-21"},"PeriodicalIF":1.2,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11999017/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144056421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Salvage lung SBRT may be a curative option after lobectomy.","authors":"Geovanne Pedro Mauro, Maria Luiza Alves José Ferioli Pereira, Mauricio José de Oliveira Costa, Heloisa A Carvalho","doi":"10.5603/rpor.104385","DOIUrl":"https://doi.org/10.5603/rpor.104385","url":null,"abstract":"<p><strong>Background: </strong>This study intends to analyze the feasibility and the outcomes of stereotactic body radiotherapy (SBRT) as a salvage treatment for lung cancer after primary surgery and compare them with the results of SBRT as the first treatment option.</p><p><strong>Materials and methods: </strong>Retrospective analysis of early-stage non-small cell lung cancer (NSCLC) treated with SBRT, either as a primary treatment or as salvage treatment after primary surgery.</p><p><strong>Results: </strong>From January 2017 to January 2022, 68 patients were analyzed. 80% were 65 years-old or above. Seven (10%) underwent SBRT as a salvage treatment after primary surgery. Most lesions treated with primary SBRT were peripheral (n = 33; 54.1%), opposed to the salvage group, where 71.4% were central lesions (n = 5). Patients who had previous surgery presented with lower forced expiratory volume in 1 second (FEV1) (p = 0.006). Median time between surgery and salvage SBRT was 35.4 months. Median follow-up was 29.3 months; median overall survival (OS) at 2 years and 3 years was, respectively, 73.5% and 67.6% (median 52.5 months), with no difference between groups. Median local, regional, and distant progression free survivals were not reached. Local control was 94.1% at 2 years and 92.6% at 3 years. Only 5 (8.2%) patients presented late grade 3-4 pneumonitis, and one, grade 5 (fatal), all in the primary SBRT group.</p><p><strong>Conclusion: </strong>SBRT as salvage after primary surgery is feasible and seems to be safe. Outcomes are expected to be equivalent to those of the patients submitted to primary SBRT.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"30 1","pages":"27-33"},"PeriodicalIF":1.2,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11999021/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144018095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute and late toxicities after moderate hypo-fractionated radiation therapy to the chest wall/breast and regional lymph nodes: a retrospective observational study.","authors":"Simonetta Saldi, Giulia Mascari, Elisabetta Perrucci, Isabella Palumbo, Gianluca Ingrosso, Anna Giulia Becchetti, Vittorio Bini, Cynthia Aristei","doi":"10.5603/rpor.104735","DOIUrl":"https://doi.org/10.5603/rpor.104735","url":null,"abstract":"<p><strong>Background: </strong>Still controversial is the optimal radiotherapy (RT) schedule for high-risk patients after mastectomy or breast conserving surgery (BCS). An alternative to conventional RT schedules is hypo-fractionation (HF) (40.5 Gy or 42.67 Gy in 15-16 fractions). The present observational, retrospective study assessed acute and late toxicities after hypo-fractionation targeting the chest wall/breast and regional lymph nodes, compared with a cohort that had received conventional fractionation. The aim was to establish the safety of hypo-fractionation in wide-field irradiation.</p><p><strong>Materials and methods: </strong>This study enrolled 80 patients (median age 63 years; range 34-83) who underwent either BCS (9) or mastectomy (71) as well as axillary lymph node dissection. The RT schedule was 40.05 Gy in 15 fractions over 3 weeks. A simultaneous integrated boost (SIB) (49.5 Gy in 15 fractions) was delivered to the tumour bed in 9 patients who received whole breast irradiation (WBI). Acute and late toxicities were graded according to Common Terminology Criteria for Adverse Events (CTCAE v4.02) and compared with outcomes in 51 patients after conventionally fractionated RT to the chest wall/breast and regional nodes. Median follow-up was 16 months (range 2.7-33.8 months).</p><p><strong>Results: </strong>All patients completed RT with no toxicity-related interruption. No patient developed any cardiac or pulmonary toxicity or ≥ grade 3 acute skin and oesophageal toxicity. Late G1 skin toxicity occurred in 9/75 patients who were eligible for analysis. No patient developed ≥ G2 late toxicity. The incidences of acute toxicity, skin rash and dysphagia were significantly lower after HF (p < 0.001 and 0.040, respectively). No significant differences emerged in late edema and skin toxicity.</p><p><strong>Conclusions: </strong>The efficacy and safety of hypofractionated regimens were confirmed in real-life settings. Present evidence supports the use of HFRT as standard treatment, providing patients with the advantages of shorter treatment times and reduced healthcare costs.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"30 1","pages":"22-26"},"PeriodicalIF":1.2,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11999014/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144057470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}